GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review.
針對超重或肥胖個體的抗藥性高血壓治療的GLP-1基礎療法:一項綜述。
EClinicalMedicine 2024-09-09
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.
GLP-1激動劑在肥胖症中的新興角色:隨機對照試驗的全面回顧。
Int J Mol Sci 2023-07-18
Role of Glucagon-Like Peptide-1 Receptor Agonists on the Weight Loss of Individuals With Type 2 Diabetes: A Systematic Review.
糖尿病患者體重減輕的系統性回顧:葡萄糖樣肽-1受體激動劑的作用。
Cureus 2023-07-18
Correlation Study of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Diabetic Patients with Hypertension.
GLP-1 受體激動劑 (GLP-1RAs) 與高血壓糖尿病患者之間的相關性研究。
Iran J Public Health 2024-08-01
Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future.
臨床上基於胰高血糖素樣肽的療法在心代謝疾病管理中的應用:過去、現在與未來。
Med Res Rev 2024-08-14
Energy balance and obesity: the emerging role of glucagon like peptide-1 receptor agonists.
能量平衡與肥胖:胰高血糖素樣肽-1 受體激動劑的新興角色。
Curr Opin Clin Nutr Metab Care 2024-08-16
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management.
肥胖中 GLP-1 生理學及基於促胰島素的藥物在慢性體重管理中的發展。
Nat Metab 2024-08-19
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension.
在代謝症候群高血壓患者管理中,胰高血糖素樣肽-1 受體激動劑 (GLP1-RAs) 的角色:來自韓國高血壓學會的立場文件。
Clin Hypertens 2024-08-31
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.
GLP-1 單一、雙重及三重受體激動劑在治療第二型糖尿病和肥胖症中的應用:敘述性回顧。
EClinicalMedicine 2024-09-16
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks.
針對肥胖的胰高血糖素樣受體-1激動劑:體重減輕結果、耐受性、副作用及風險。
Obes Pillars 2024-09-17